Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region
March 12, 2019 09:18 ET
|
Nemaura Medical Inc
Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – March 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of...
Nemaura Reports Third Quarter 2018 Financial Results
February 12, 2019 09:15 ET
|
Nemaura Medical Inc
Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible...
Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development
February 11, 2019 08:00 ET
|
Nemaura Medical Inc
Dr. Schaebsdau to Advance European Launch of SugarBEAT® Continuous Glucose Monitor Nemaura Preparing U.S. FDA 510(k) Submission Loughborough, England – February 11, 2019 – Nemaura Medical,...
Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm
February 07, 2019 09:00 ET
|
Nemaura Medical Inc
Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...
Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor
January 17, 2019 09:00 ET
|
Nemaura Medical Inc
Loughborough, England –Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible...
Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval
December 21, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments
December 19, 2018 08:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial
December 18, 2018 09:00 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering
December 18, 2018 08:40 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by...
Nemaura Medical Announces Proposed Public Offering
December 17, 2018 17:15 ET
|
Nemaura Medical Inc
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...